Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06706232 · ClinicalTrials.gov registry record · Phase 2
Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and Suicidality
A Phase 2 study of Bipolar II Disorder and Depression, Bipolar, sponsored by The University of Texas Health Science Center, Houston.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT06706232: Recruiting Phase 2 study of Bipolar II Disorder and Depression, Bipolar, sponsored by The University of Texas Health Science Center, Houston.
NCT06706232 is a Phase 2 study of Bipolar II Disorder and Depression, Bipolar that is actively recruiting participants, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 10 participants, below the 82-participant average among 14 other Bipolar II Disorder trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06706232, a Phase 2 study of Bipolar II Disorder and Depression, Bipolar, is actively recruiting participants, sponsored by The University of Texas Health Science Center, Houston.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to assess the safety and acceptability of up to two sequential administrations of 25 mg psilocybin with additional therapeutic support in decreasing suicidality in patients with Bipolar Disorder (BD II) depression.
Primary Outcome
This is assessed by number of participants who complete the trial, that is, the number of participants who complete the first dose and follow-up visits up to 3 weeks after the first dose.
Conditions Studied
Interventions
- DRUG Psilocybin
- BEHAVIORAL Therapeutic Support
Study Locations (1)
Texas
- The University of Texas Health Science Center at Houston - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2025-07-07 |
| Est. Completion | 2027-01 |
| Phase | Phase 2 |
What NCT06706232 shows while recruiting
NCT06706232 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 82-participant average among 14 other Bipolar II Disorder trials with a reported enrollment target (88% lower).
The record links to 3 conditions, with Bipolar II Disorder appearing as the primary indexed condition, and to 2 interventions - of which Psilocybin is the first listed.
NCT06706232 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06706232 about?
NCT06706232 is a clinical study titled "Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and Suicidality". The purpose of the study is to assess the safety and acceptability of up to two sequential administrations of 25 mg psilocybin with additional therapeutic support in decreasing suicidality in patients with Bipolar Disorder (BD II) depression.
What is the current status of trial NCT06706232?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2025-07-07. Estimated completion is 2027-01.
What conditions does trial NCT06706232 study?
This clinical trial studies the following conditions: Bipolar II Disorder, Depression, Bipolar, Suicidality.
What interventions are being tested in trial NCT06706232?
The interventions under investigation include: Psilocybin (DRUG), Therapeutic Support (BEHAVIORAL).
Who is sponsoring clinical trial NCT06706232?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06706232 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bipolar II Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06706232's enrollment target sits among peer trials
10 14th of 14 the lowest of 14 other Bipolar II Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Bipolar II Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Gabapentin for Restoring GABA/Glutamate Homeostasis in Co-occurring Bipolar and Cannabis Use Disorders
RECRUITING · Phase 2
-
A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder
RECRUITING · Phase 2
-
Psilocybin Therapy for Depression in Bipolar II Disorder
ACTIVE NOT RECRUITING · Phase 2
-
Assessment of Acute Psychomotor Agitation Measures Associated With Schizophrenia and Bipolar Disorder
ACTIVE NOT RECRUITING · Phase 2
-
Treating Smokers With Mental Illness
COMPLETED · Phase 2
-
Psychotherapy for Bipolar II Depression, Pilot Study, Phase II
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI